Intranasal calcitonin in the treatment of acute Charcot neuroosteoarthropathy: a randomized controlled trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN91576704

Enrollment

Registered

2006-01-13

Start date

2003-08-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic Foot Nutritional, Metabolic, Endocrine Acute charcot foot

Interventions

Intranasal Calcitonin 200 IU + Calcium 1000 mg per day or Calcium 1000 mg per day in monotherapy

two years follow-up period.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Acute Charcot foot 2. Type 1 or Type 2 Diabetes

Exclusion criteria

Exclusion criteria: 1. Foot ulcer 2. Acute osteomyelitis

Design outcomes

Primary

Measure	Time frame
1. Effect on bone remodeling markers 2. Markers of disease activity - skin temperature	—

Secondary

Measure	Time frame
1. Prevention of deformities 2. Shortening of the treatment 3. Recurrence of Charcot foot	—

Countries

Czech Republic

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026